Related Experiment Videos

Intervention in gastro-enteropancreatic neuroendocrine tumours

Eric Baudin1, David Planchard, Jean-Yves Scoazec

  • 1Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. baudin@igr.fr

Best Practice & Research. Clinical Gastroenterology
|April 16, 2013
PubMed

Insights

Neuroendocrine tumors (NET) require interventions for hormone secretion and tumor growth. Managing hormone symptoms is crucial for effective treatment strategies in GEP NET patients.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Neuroendocrine tumors (NET) present challenges due to hormone secretion and heterogeneous tumor growth.
  • Effective management requires addressing both hormonal symptoms and antitumour strategies.
  • Well-differentiated NET exhibit significant prognostic heterogeneity, complicating treatment decisions.

Purpose of the Study:

  • To review timely therapeutic interventions for hormone symptom control and tumor growth in gastroenteropancreatic (GEP) NET patients.
  • To emphasize the importance of managing hormone-related symptoms as a primary step in NET treatment.
  • To discuss expected progress in recognizing prognostic subgroups of well-differentiated NET.

Main Methods:

  • Review of current literature on neuroendocrine tumor management.
  • Analysis of therapeutic strategies for hormone secretion and tumor growth.
  • Discussion of prognostic factors and subgroup recognition in well-differentiated NET.

Main Results:

  • Early intervention for hormone symptoms and poorly differentiated NET is recommended.
  • Tumor growth control strategies are complex in well-differentiated NET due to prognostic heterogeneity.
  • Controlling hormone symptoms is a prerequisite for effective tumor growth control.

Conclusions:

  • Integrated strategies are essential for managing GEP NET, addressing both hormonal and neoplastic aspects.
  • Further research is needed to refine prognostic stratification for well-differentiated NET.
  • Advances in recognizing NET subgroups will improve tailored therapeutic interventions.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Endoscopic Procedures V: ERCP01:26

Endoscopic Procedures V: ERCP

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...